Quality-of-life measurements are essential in cancer care, study says

As novel cancer treatments continually emerge, it is essential to collect data on patients’ quality of life along with how the treatment is working to extend survival.

Novartis’ urticaria drug meets all endpoints in Phase III trials – Pharmaceutical Technology

Remibrutinib is forecasted to generate $237m in 2034 in US sales, as per GlobalData’s Expiry model. Image Credit: Michael Derrer Fuchs / Shutterstock. Novartis’ remibrutinib

November 10, 2023

Roche gains rights for Ionis’ Alzheimer’s, Huntington’s programmes

The companies will develop two programmes for treating Alzheimer’s disease and Huntington’s disease. Credit: Chinnapong/Shutterstock.com. Roche has signed an agreement to attain exclusive global rights to Ionis

September 28, 2023

Abivax provides business and operational update – Biotech Investments

EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax provides business and operational update 07.09.2023 / 08:00 CET/CEST The issuer is solely responsible for the content of

September 8, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.